Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regeneron | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Regeneron

Sales of EYLEA up 16% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron

3Q Revenues: $1.2 billion (7%)

3Q Earnings: $265.0 million (+26%)

YTD Revenues: $3.6 billion (+21%)

YTD Earnings: $642.4 million (+34%)

Comments: Product sales were $857 million in the quarter, up 16%. Sales of EYLEA in the U.S. increased 16% to $854 million in the quarter. Sales of Praluent were $38 million, compared to $4 million in 3Q15 when the product was launched in the U.S. Product sales for Praluent are recorded by Sanofi, and the company shares in any profits or losses from the commercialization of Praluent. R&D expenses were $543 million in the quarter, up 27% primarily related to the $25 million up-front payment in connection with the Adicet collaboration.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters